Ken Garber

2 months ago | annarborobserver.com | Ken Garber |Brooke Black

The Trump administration’s drive to disrupt the federal government is already having an outsized effect on Ann Arbor, from social services to climate activism. (For the impact on just one nonprofit, see Doomsday Planning.) But none matches the economic destruction threatened by a February announcement from the National Institutes of Health, which provides $800 million of the U-M’s $2 billion in annual research funding. The edict would set grantees’ “indirect cost” reimbursement at 15 percent.

2 months ago | nature.com | Ken Garber

Nature Reviews Drug Discovery (Nat Rev Drug Discov) ISSN 1474-1784 (online) ISSN 1474-1776 (print)

Aug 26, 2024 | annarborobserver.com | Ken Garber |Amy Sumerton

Just before kick-off at the AFC Ann Arbor women’s May 19 soccer match against Kalamazoo FC at Pioneer High School’s Hollway Field, fifteen-year-old Izzy Sutton and two U-M students received formal recognition as female leaders and role models. Sutton, tall and athletic, was a 2023 Washtenaw County Young Citizen of the Year, and has won state and national service awards for her work, which has included raising money for bird and turtle rescue by selling her own line of notecards.

Aug 20, 2024 | nature.com | Ken Garber

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. A rescued chimeric antigen receptor from Cargo Therapeutics for hard-to-treat lymphomas shows promise in patients while a trispecific advances toward human testing.

Jun 21, 2024 | nature.com | Ken Garber

NEWS 21 June 2024 Small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias. An important new class of drugs for acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL) could soon secure FDA approval. The agency should decide on Syndax’s first-in-class menin inhibitor revumenib by late September.